Are GLP-1 Medications FDA-Approved for Alcohol Use Disorder?

Direct Answer

No. As of 2026, no GLP-1 medication holds FDA approval to treat alcohol use disorder (AUD). Every GLP-1 drug currently on the market is approved for specific, different conditions, and AUD is not one of them.

What GLP-1 Medications Are Actually Approved For

Ozempic (semaglutide) is approved for type 2 diabetes. Wegovy (semaglutide) is approved for chronic weight management and, since March 2024, for reducing cardiovascular risk in adults with obesity and heart disease. Mounjaro and Zepbound (tirzepatide) are approved for type 2 diabetes and weight management, respectively. None of these approvals extend to alcohol use disorder, regardless of the underlying molecule.

Approved Use vs. Investigational Research

These are two genuinely different things. An FDA-approved use means the drug has completed the full regulatory review process for that specific condition, phase 3 trials, safety data, and formal FDA sign-off. Investigational research, which is where GLP-1 medications and AUD currently stand, means clinical trials are actively studying the question, but no regulatory body has yet reviewed and approved that use.

What "Off-Label" Prescribing Means

A physician can legally prescribe an FDA-approved drug for a use outside its approved indication, this is called off-label prescribing, and it happens across medicine for many drugs. It is a real, legal practice, but it is not the same as the drug being approved for that use, and it means the specific safety and efficacy data for that use hasn't gone through the same formal review. This explainer does not encourage off-label use; that decision belongs between a patient and their physician.

What Would Need to Happen for FDA Approval

For a GLP-1 medication to receive an FDA indication for AUD, a drug sponsor would need to complete large-scale, phase 3 randomized controlled trials specifically designed to test safety and efficacy for AUD, then submit that data to the FDA for formal review. The current research, including the VA's nationwide trial that launched in 2026, represents real, active steps in that direction, but is not the final step. This process realistically takes years, not months, even when early results are promising.

What to Understand When You See Headlines About This

Promising research results, even from real, peer-reviewed, randomized trials, are not the same as regulatory approval. When you see a headline about GLP-1 medications and alcohol use disorder, it's worth checking specifically whether it's describing a completed approval (currently, none exist) or ongoing research (which does exist and is real). The distinction matters directly for what any of this means for you today.

Bottom Line

Real, legitimate research into GLP-1 medications for alcohol use disorder is underway, but no FDA approval exists as of 2026. Established, currently approved treatments for AUD remain the appropriate starting point for anyone seeking treatment today.

For the Full Research Picture

See what the current evidence actually shows for a complete summary of the clinical trial data behind this research area.

References

• U.S. Food and Drug Administration, approval records for semaglutide and tirzepatide products
• U.S. Department of Veterans Affairs: VA Launches Trial of GLP-1 Treatment for Alcohol Use Disorder (July 2026)

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

This article is for general informational purposes and is not medical advice. If you are experiencing a mental health or substance use crisis, please seek immediate professional support. SAMHSA National Helpline: 1-800-662-4357.